JP2016517851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517851A5 JP2016517851A5 JP2016507995A JP2016507995A JP2016517851A5 JP 2016517851 A5 JP2016517851 A5 JP 2016517851A5 JP 2016507995 A JP2016507995 A JP 2016507995A JP 2016507995 A JP2016507995 A JP 2016507995A JP 2016517851 A5 JP2016517851 A5 JP 2016517851A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- unsubstituted
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013074323 | 2013-04-17 | ||
| CNPCT/CN2013/074323 | 2013-04-17 | ||
| PCT/CN2014/075594 WO2014169833A1 (en) | 2013-04-17 | 2014-04-17 | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018164995A Division JP6784735B2 (ja) | 2013-04-17 | 2018-09-04 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2018164996A Division JP6710730B2 (ja) | 2013-04-17 | 2018-09-04 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517851A JP2016517851A (ja) | 2016-06-20 |
| JP2016517851A5 true JP2016517851A5 (enExample) | 2017-06-01 |
| JP6470258B2 JP6470258B2 (ja) | 2019-02-13 |
Family
ID=51730809
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507995A Active JP6470258B2 (ja) | 2013-04-17 | 2014-04-17 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2018164995A Active JP6784735B2 (ja) | 2013-04-17 | 2018-09-04 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2018164996A Active JP6710730B2 (ja) | 2013-04-17 | 2018-09-04 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2020161921A Active JP7085601B2 (ja) | 2013-04-17 | 2020-09-28 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2022010037A Active JP7527318B2 (ja) | 2013-04-17 | 2022-01-26 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2023129979A Active JP7668850B2 (ja) | 2013-04-17 | 2023-08-09 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2024232815A Pending JP2025060975A (ja) | 2013-04-17 | 2024-12-27 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018164995A Active JP6784735B2 (ja) | 2013-04-17 | 2018-09-04 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2018164996A Active JP6710730B2 (ja) | 2013-04-17 | 2018-09-04 | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2020161921A Active JP7085601B2 (ja) | 2013-04-17 | 2020-09-28 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2022010037A Active JP7527318B2 (ja) | 2013-04-17 | 2022-01-26 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2023129979A Active JP7668850B2 (ja) | 2013-04-17 | 2023-08-09 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
| JP2024232815A Pending JP2025060975A (ja) | 2013-04-17 | 2024-12-27 | １９－ノルｃ３，３－ジ置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US9512165B2 (enExample) |
| EP (4) | EP3909966B1 (enExample) |
| JP (7) | JP6470258B2 (enExample) |
| KR (4) | KR102239541B1 (enExample) |
| CN (4) | CN113527400B (enExample) |
| AU (5) | AU2014256229B2 (enExample) |
| BR (1) | BR112015026380A8 (enExample) |
| CA (1) | CA2909545A1 (enExample) |
| CY (2) | CY1121228T1 (enExample) |
| DK (3) | DK3909966T3 (enExample) |
| ES (3) | ES2886182T3 (enExample) |
| HR (2) | HRP20190232T1 (enExample) |
| HU (2) | HUE041369T2 (enExample) |
| IL (4) | IL286794B2 (enExample) |
| LT (2) | LT3498725T (enExample) |
| MX (3) | MX362543B (enExample) |
| PL (2) | PL3498725T3 (enExample) |
| PT (2) | PT3498725T (enExample) |
| RS (2) | RS58297B1 (enExample) |
| RU (1) | RU2675855C2 (enExample) |
| SG (2) | SG10201802389SA (enExample) |
| SI (2) | SI2986623T1 (enExample) |
| SM (2) | SMT201900066T1 (enExample) |
| TR (1) | TR201901745T4 (enExample) |
| WO (1) | WO2014169833A1 (enExample) |
| ZA (1) | ZA201507740B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| NZ627781A (en) | 2012-01-23 | 2016-10-28 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| SG10201608148TA (en) | 2012-08-21 | 2016-11-29 | Sage Therapeutics Inc | Methods Of Treating Epilepsy Or Status Epilepticus |
| DK2986624T3 (da) | 2013-04-17 | 2020-06-29 | Sage Therapeutics Inc | Neuroaktive 19-nor-steroider til terapeutisk anvendelse |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| PL3498725T3 (pl) | 2013-04-17 | 2021-11-08 | Sage Therapeutics, Inc. | 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii |
| EP3021852B1 (en) | 2013-07-19 | 2021-01-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| PE20170925A1 (es) | 2014-10-16 | 2017-07-13 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del snc |
| ES2808855T3 (es) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| CN104558092B (zh) * | 2014-12-29 | 2017-01-18 | 北京理工大学 | 一种甾体皂苷化合物及其制备方法和用途 |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| CN104910236B (zh) * | 2015-06-26 | 2016-08-17 | 西北农林科技大学农药研究所 | 吡唑基甾体衍生物及其制备方法、用途 |
| WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| CA3279953A1 (en) * | 2016-07-11 | 2025-11-29 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP4302764A3 (en) | 2016-07-11 | 2024-06-26 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| BR112019003637A2 (pt) | 2016-08-23 | 2019-08-06 | Sage Therapeutics Inc | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| IL270962B2 (en) * | 2017-06-01 | 2023-09-01 | Sumitomo Chemical Co | A heterocyclic compound and a mixture containing it |
| IL303250A (en) * | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| US20220110949A1 (en) * | 2017-09-14 | 2022-04-14 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20210228596A1 (en) * | 2017-10-12 | 2021-07-29 | Sage Therapeutics, Inc. | Method of treating cns disorders with neurosteroids and gabaergic compounds |
| JP2021505608A (ja) * | 2017-12-08 | 2021-02-18 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体 |
| AU2018392093B2 (en) | 2017-12-22 | 2024-02-01 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| IL310454A (en) * | 2017-12-22 | 2024-03-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| EP3737687B1 (en) * | 2018-01-12 | 2025-10-22 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
| WO2019154257A1 (zh) * | 2018-02-11 | 2019-08-15 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| MX2020008182A (es) * | 2018-02-11 | 2020-09-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos. |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN111040015B (zh) * | 2018-10-15 | 2022-03-18 | 南京诺瑞特医药科技有限公司 | 19-去甲-c21取代类固醇衍生物 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| KR102892974B1 (ko) | 2018-12-05 | 2025-11-28 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CA3121636A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Analogs of (3alpha,5alpha)-3-hydroxy-21-(1h-imidazol-1-yl)-3-methoxymethyl)-pregnan-20-one |
| CN116425819B (zh) * | 2019-01-08 | 2025-10-03 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| CA3124703C (en) * | 2019-01-14 | 2023-10-17 | Beijing Xuanyi Pharmasciences Co., Ltd. | Tetrazolone substituted steroids and use thereof |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| US12122804B2 (en) | 2019-01-31 | 2024-10-22 | Shenzhen Rentai Pharmatech Ltd. | γ-aminobutyric acid modulator crystal form X, preparation method and application thereof |
| KR20220006565A (ko) | 2019-05-10 | 2022-01-17 | 브리 바이오사이언시스, 인크. | 브렉사놀론, 가낙솔론, 또는 주라놀론을 함유하는 약제 조성물, 및 이것의 용도 |
| WO2020242772A1 (en) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| BR112021024033A2 (pt) * | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| TWI896547B (zh) * | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| TWI896548B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| EP3990467A1 (en) * | 2019-06-27 | 2022-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| WO2021023213A1 (zh) * | 2019-08-07 | 2021-02-11 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| KR20220103707A (ko) * | 2019-09-30 | 2022-07-22 | 엘리엄 테라퓨틱스 (유케이) 엘티디 | Gabaa 수용체의 아형을 우선적으로 강화시키는 조성물 및 그의 사용 방법 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| AU2020395246A1 (en) * | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| CN114828889B (zh) | 2019-12-06 | 2025-02-14 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| EP4125921A1 (en) * | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| WO2022020363A1 (en) * | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CA3206537A1 (en) * | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| BR112023018607A2 (pt) | 2021-03-17 | 2023-10-24 | Sage Therapeutics Inc | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
| US20240216396A1 (en) | 2021-04-29 | 2024-07-04 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| AU2022266680A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| TW202341995A (zh) | 2022-02-16 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療cns相關病症之神經活性類固醇 |
| WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| IL320996A (en) | 2022-11-21 | 2025-07-01 | Sage Therapeutics Inc | Negative NMDA modulator compounds and methods of using them |
| EP4680616A1 (en) | 2023-03-14 | 2026-01-21 | Curia Spain, S.A.U. | Process and intermediates for the preparation of 3alpha-hydroxy-3beta-alkyl steroids |
| WO2024230797A1 (zh) | 2023-05-11 | 2024-11-14 | 上海枢境生物科技有限公司 | 甾体类化合物、制备方法及其用途 |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| NL297205A (enExample) * | 1962-08-28 | |||
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| US3511860A (en) * | 1966-09-26 | 1970-05-12 | Syntex Corp | Synthesis of 19-nor and ring a aromatic steroids and intermediates therefor |
| NL6801449A (enExample) * | 1968-02-01 | 1969-08-05 | ||
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| DK134348C (da) | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2118938A1 (en) | 1991-09-13 | 1993-04-01 | Kelvin W. Gee | Novel gabaa receptor with steroid binding sites |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| US5567830A (en) | 1994-02-14 | 1996-10-22 | Cocensys, Inc. | Process for synthesis of acetylenic carbinols |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| EP0752860B1 (en) * | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| WO1996003421A1 (en) | 1994-07-21 | 1996-02-08 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| US5792757A (en) * | 1994-08-04 | 1998-08-11 | Pherin Pharmaceuticals | 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function |
| AP653A (en) | 1994-11-23 | 1998-07-21 | Cocensys Inc | Androstane and pregnane series for allosteric modulations of gaba receptor. |
| US5925630A (en) | 1995-06-06 | 1999-07-20 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| IL146230A0 (en) * | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| US6717002B2 (en) | 2000-02-18 | 2004-04-06 | Taiho Pharmaceutical Co., Ltd. | Method of producing steroid derivatives |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| US6844456B2 (en) | 2000-11-03 | 2005-01-18 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| JP4719144B2 (ja) | 2003-03-24 | 2011-07-06 | ステリックス リミテッド | ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| US20070099880A1 (en) | 2003-11-24 | 2007-05-03 | Blizzard Timothy A | Estrogen receptor modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| AU2005282727A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Substituted heterocyclic compounds and uses thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| AU2005330504B2 (en) | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| SI2168585T1 (sl) | 2005-06-09 | 2012-04-30 | Euro Celtique Sa | Farmacevtski sestavki nevroaktivnega steroida in njihove uporabe |
| CN100362013C (zh) * | 2006-03-16 | 2008-01-16 | 中国科学院上海有机化学研究所 | 一类c22-羰基甾体化合物、合成方法及其用途 |
| KR20090006148A (ko) * | 2006-04-05 | 2009-01-14 | 와이어쓰 | 5-히드록시트립타민-6 리간드로서의 설포닐-3-헤테로시클릴인다졸 유도체 |
| CN101506221B (zh) * | 2006-09-19 | 2012-09-12 | 索尔瓦药物有限公司 | 雌三烯衍生物及其作为17β-羟基类固醇脱氢酶抑制剂的用途 |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| EP2155204B1 (en) | 2007-06-15 | 2016-08-17 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| KR100958286B1 (ko) * | 2007-11-15 | 2010-05-19 | 한국과학기술원 | ａ１Ｇ Ｔ―타입 칼슘 채널을 억제하여 본태성 진전증을예방 및 치료하는 방법 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| US20100120733A1 (en) | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| AU2011284606A1 (en) | 2010-07-30 | 2013-03-14 | Pharmacellion Ltd | Compounds and methods for treating neoplasia |
| CN103347525A (zh) | 2010-12-15 | 2013-10-09 | 哈博生物科学公司 | 制备3α-氧取代的甾族化合物的方法及化合物 |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP5265816B2 (ja) | 2011-03-23 | 2013-08-14 | 悦朗 伊藤 | タンパク質および核酸の超高感度測定法およびキット、並びに新規な酵素基質 |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| EP4245369A3 (en) * | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| NZ627781A (en) | 2012-01-23 | 2016-10-28 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| SG10201608148TA (en) | 2012-08-21 | 2016-11-29 | Sage Therapeutics Inc | Methods Of Treating Epilepsy Or Status Epilepticus |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2916846B1 (en) | 2012-11-09 | 2025-09-17 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| ES2973320T3 (es) | 2012-11-30 | 2024-06-19 | Univ California | Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto |
| EP3392260B1 (en) | 2012-12-18 | 2022-09-21 | Washington University | Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| PL3498725T3 (pl) | 2013-04-17 | 2021-11-08 | Sage Therapeutics, Inc. | 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| DK2986624T3 (da) | 2013-04-17 | 2020-06-29 | Sage Therapeutics Inc | Neuroaktive 19-nor-steroider til terapeutisk anvendelse |
| EP3021852B1 (en) | 2013-07-19 | 2021-01-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| CA2949720C (en) | 2014-05-29 | 2025-11-18 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS, THEIR COMPOSITION AND USES |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3188734A4 (en) | 2014-09-02 | 2018-01-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ES2808855T3 (es) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
| PE20170925A1 (es) | 2014-10-16 | 2017-07-13 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del snc |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016164763A1 (en) | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CN108350021A (zh) | 2015-09-08 | 2018-07-31 | 视点医疗公司 | 用于治疗眼科疾病的化合物和制剂 |
| WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CA3279953A1 (en) | 2016-07-11 | 2025-11-29 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP4302764A3 (en) | 2016-07-11 | 2024-06-26 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| BR112019003637A2 (pt) | 2016-08-23 | 2019-08-06 | Sage Therapeutics Inc | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| MX2020001732A (es) | 2017-08-31 | 2020-03-20 | Takeda Pharmaceuticals Co | Tratamiento de las afecciones del sistema nervioso central. |
| IL303250A (en) | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| US20220110949A1 (en) | 2017-09-14 | 2022-04-14 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20190160078A1 (en) | 2017-11-10 | 2019-05-30 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
| JP2021505608A (ja) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体 |
| AU2018392093B2 (en) | 2017-12-22 | 2024-02-01 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| IL310454A (en) | 2017-12-22 | 2024-03-01 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| EP3737687B1 (en) | 2018-01-12 | 2025-10-22 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
| UY38213A (es) | 2018-05-04 | 2019-10-31 | Acerus Pharmaceuticals Corp | Derivados de neuroesteroides y usos de estos |
| CA3103421A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CA3115805A1 (en) | 2018-10-12 | 2020-04-16 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| BR112021007401A2 (pt) | 2018-10-19 | 2021-08-03 | Sage Therapeutics, Inc. | esteroides neuroativos insaturados 9(11) e seus métodos de uso |
| KR102892974B1 (ko) | 2018-12-05 | 2025-11-28 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| TWI892697B (zh) | 2018-12-21 | 2025-08-01 | 美商賽吉醫療公司 | 神經活性類固醇及其組合物 |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| TWI896548B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| EP3990467A1 (en) | 2019-06-27 | 2022-05-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI896547B (zh) | 2019-06-27 | 2025-09-11 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| AU2020395246A1 (en) | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| TW202143976A (zh) | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| IL299176A (en) | 2020-06-24 | 2023-02-01 | Sage Therapeutics Inc | Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds |
| WO2022020363A1 (en) | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| JP2023550653A (ja) | 2020-11-25 | 2023-12-04 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓの障害を治療するための組成物及び方法 |
| CA3206537A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| BR112023018607A2 (pt) | 2021-03-17 | 2023-10-24 | Sage Therapeutics Inc | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
| EP4322960A1 (en) | 2021-04-12 | 2024-02-21 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| AU2022266680A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| US20240216396A1 (en) | 2021-04-29 | 2024-07-04 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| TW202341995A (zh) | 2022-02-16 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療cns相關病症之神經活性類固醇 |
| WO2023163879A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
-
2014
- 2014-04-17 PL PL18203320T patent/PL3498725T3/pl unknown
- 2014-04-17 HR HRP20190232TT patent/HRP20190232T1/hr unknown
- 2014-04-17 MX MX2015014600A patent/MX362543B/es active IP Right Grant
- 2014-04-17 KR KR1020157032454A patent/KR102239541B1/ko active Active
- 2014-04-17 CN CN202110717941.7A patent/CN113527400B/zh active Active
- 2014-04-17 BR BR112015026380A patent/BR112015026380A8/pt not_active Application Discontinuation
- 2014-04-17 MX MX2019000996A patent/MX395023B/es unknown
- 2014-04-17 KR KR1020237042912A patent/KR20230172622A/ko active Pending
- 2014-04-17 LT LTEP18203320.9T patent/LT3498725T/lt unknown
- 2014-04-17 CN CN202410741773.9A patent/CN118754924A/zh active Pending
- 2014-04-17 PT PT182033209T patent/PT3498725T/pt unknown
- 2014-04-17 KR KR1020217010184A patent/KR102396328B1/ko active Active
- 2014-04-17 EP EP21178047.3A patent/EP3909966B1/en active Active
- 2014-04-17 DK DK21178047.3T patent/DK3909966T3/da active
- 2014-04-17 EP EP14785712.2A patent/EP2986623B1/en active Active
- 2014-04-17 IL IL286794A patent/IL286794B2/en unknown
- 2014-04-17 ES ES18203320T patent/ES2886182T3/es active Active
- 2014-04-17 PL PL14785712T patent/PL2986623T3/pl unknown
- 2014-04-17 SI SI201431072T patent/SI2986623T1/sl unknown
- 2014-04-17 RU RU2015149008A patent/RU2675855C2/ru active
- 2014-04-17 CN CN201810263557.2A patent/CN108440633B/zh active Active
- 2014-04-17 DK DK14785712.2T patent/DK2986623T3/en active
- 2014-04-17 CN CN201480031476.XA patent/CN105339381B/zh active Active
- 2014-04-17 LT LTEP14785712.2T patent/LT2986623T/lt unknown
- 2014-04-17 RS RS20190136A patent/RS58297B1/sr unknown
- 2014-04-17 ES ES14785712T patent/ES2709434T3/es active Active
- 2014-04-17 WO PCT/CN2014/075594 patent/WO2014169833A1/en not_active Ceased
- 2014-04-17 DK DK18203320.9T patent/DK3498725T3/da active
- 2014-04-17 EP EP25185895.7A patent/EP4640277A3/en active Pending
- 2014-04-17 HU HUE14785712A patent/HUE041369T2/hu unknown
- 2014-04-17 SI SI201431867T patent/SI3498725T1/sl unknown
- 2014-04-17 HU HUE18203320A patent/HUE055554T2/hu unknown
- 2014-04-17 AU AU2014256229A patent/AU2014256229B2/en active Active
- 2014-04-17 ES ES21178047T patent/ES3044385T3/es active Active
- 2014-04-17 TR TR2019/01745T patent/TR201901745T4/tr unknown
- 2014-04-17 KR KR1020227015252A patent/KR102614507B1/ko active Active
- 2014-04-17 SM SM20190066T patent/SMT201900066T1/it unknown
- 2014-04-17 RS RS20211106A patent/RS62312B1/sr unknown
- 2014-04-17 US US14/785,171 patent/US9512165B2/en active Active
- 2014-04-17 PT PT14785712T patent/PT2986623T/pt unknown
- 2014-04-17 EP EP18203320.9A patent/EP3498725B1/en active Active
- 2014-04-17 SM SM20210509T patent/SMT202100509T1/it unknown
- 2014-04-17 JP JP2016507995A patent/JP6470258B2/ja active Active
- 2014-04-17 SG SG10201802389SA patent/SG10201802389SA/en unknown
- 2014-04-17 SG SG11201508550XA patent/SG11201508550XA/en unknown
- 2014-04-17 CA CA2909545A patent/CA2909545A1/en active Pending
- 2014-04-17 IL IL310348A patent/IL310348A/en unknown
-
2015
- 2015-10-15 ZA ZA2015/07740A patent/ZA201507740B/en unknown
- 2015-10-15 IL IL242089A patent/IL242089B/en active IP Right Grant
- 2015-10-16 MX MX2022007490A patent/MX2022007490A/es unknown
-
2016
- 2016-10-19 US US15/297,845 patent/US10172871B2/en active Active
-
2018
- 2018-06-27 US US16/020,641 patent/US10342810B2/en active Active
- 2018-09-04 JP JP2018164995A patent/JP6784735B2/ja active Active
- 2018-09-04 JP JP2018164996A patent/JP6710730B2/ja active Active
- 2018-12-11 AU AU2018278844A patent/AU2018278844B2/en active Active
-
2019
- 2019-02-05 CY CY20191100154T patent/CY1121228T1/el unknown
- 2019-05-31 US US16/428,386 patent/US11241446B2/en active Active
-
2020
- 2020-09-28 JP JP2020161921A patent/JP7085601B2/ja active Active
- 2020-10-15 AU AU2020256400A patent/AU2020256400B2/en active Active
- 2020-11-04 IL IL278487A patent/IL278487B/en unknown
-
2021
- 2021-08-13 HR HRP20211314TT patent/HRP20211314T1/hr unknown
- 2021-09-07 CY CY20211100787T patent/CY1125416T1/el unknown
- 2021-12-23 US US17/560,732 patent/US12201640B2/en active Active
-
2022
- 2022-01-26 JP JP2022010037A patent/JP7527318B2/ja active Active
- 2022-07-12 AU AU2022205157A patent/AU2022205157B2/en active Active
-
2023
- 2023-08-09 JP JP2023129979A patent/JP7668850B2/ja active Active
-
2024
- 2024-12-10 US US18/975,467 patent/US20250319106A1/en active Pending
- 2024-12-12 AU AU2024278325A patent/AU2024278325A1/en active Pending
- 2024-12-27 JP JP2024232815A patent/JP2025060975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517851A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| RU2015149008A (ru) | 19-нор c3, 3-дизамещенные c21-n-пиразолильные стероиды и способы их применения | |
| JP2016512531A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2019519587A5 (enExample) | ||
| JP2015509098A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2019517487A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2017531019A5 (enExample) | ||
| JP2013209405A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2013519675A5 (enExample) | ||
| JP2011502153A5 (enExample) | ||
| JP2018534288A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2014515351A5 (enExample) | ||
| JP2016525121A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2016510326A5 (enExample) |